Mogy Joel R Investment Counsel Inc. increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 0.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 143,119 shares of the biopharmaceutical company’s stock after acquiring an additional 115 shares during the period. Mogy Joel R Investment Counsel Inc.’s holdings in Pfizer were worth $4,807,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of PFE. Canada Pension Plan Investment Board grew its holdings in Pfizer by 249.6% during the second quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock worth $359,871,000 after acquiring an additional 7,649,416 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in Pfizer by 6.4% during the second quarter. Schwab Charles Investment Management Inc. now owns 33,274,658 shares of the biopharmaceutical company’s stock worth $1,117,696,000 after acquiring an additional 2,013,835 shares during the period. Boston Partners grew its holdings in Pfizer by 7.3% during the first quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock worth $830,071,000 after acquiring an additional 1,649,801 shares during the period. Sanders Capital LLC grew its holdings in Pfizer by 10.8% during the second quarter. Sanders Capital LLC now owns 16,933,077 shares of the biopharmaceutical company’s stock worth $626,222,000 after acquiring an additional 1,644,036 shares during the period. Finally, Bank of Nova Scotia grew its holdings in Pfizer by 325.9% during the first quarter. Bank of Nova Scotia now owns 1,934,514 shares of the biopharmaceutical company’s stock worth $66,180,000 after acquiring an additional 1,480,258 shares during the period. 69.34% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts recently commented on PFE shares. Cowen Inc set a $43.00 target price on Pfizer and gave the stock a “buy” rating in a report on Monday, August 14th. Jefferies Group LLC set a $35.00 target price on Pfizer and gave the stock a “neutral” rating in a report on Thursday, August 24th. Berenberg Bank reiterated a “hold” rating and set a $36.00 price target (down previously from $39.00) on shares of Pfizer in a research report on Tuesday, August 15th. Deutsche Bank AG set a $38.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, October 11th. Finally, Goldman Sachs Group Inc set a $36.00 price target on Pfizer and gave the stock a “neutral” rating in a research report on Wednesday, November 1st. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $38.66.

In other news, insider Alexander R. Mackenzie sold 14,700 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total value of $518,910.00. Following the transaction, the insider now owns 117,432 shares in the company, valued at $4,145,349.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $35.65, for a total value of $262,027.50. Following the completion of the transaction, the executive vice president now owns 117,432 shares in the company, valued at approximately $4,186,450.80. The disclosure for this sale can be found here. In the last 90 days, insiders sold 366,557 shares of company stock worth $12,532,406. Company insiders own 0.06% of the company’s stock.

Shares of Pfizer Inc. (NYSE PFE) traded up $0.05 during mid-day trading on Friday, reaching $35.49. The company’s stock had a trading volume of 6,400,000 shares, compared to its average volume of 14,047,984. The stock has a market capitalization of $211,545.50, a P/E ratio of 14.20, a P/E/G ratio of 2.51 and a beta of 1.01. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. Pfizer Inc. has a 52 week low of $30.51 and a 52 week high of $36.78.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter last year, the business posted $0.61 earnings per share. equities research analysts anticipate that Pfizer Inc. will post 2.6 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be given a $0.32 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 annualized dividend and a dividend yield of 3.61%. Pfizer’s dividend payout ratio (DPR) is presently 79.01%.

WARNING: “Mogy Joel R Investment Counsel Inc. Has $4.81 Million Position in Pfizer Inc. (PFE)” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.watchlistnews.com/mogy-joel-r-investment-counsel-inc-has-4-81-million-position-in-pfizer-inc-pfe/1727569.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.